12/10
07:16 am
rdhl
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development [Yahoo! Finance]
High
Report
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development [Yahoo! Finance]
12/10
07:00 am
rdhl
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Medium
Report
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
12/2
07:10 am
rdhl
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court [Yahoo! Finance]
High
Report
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court [Yahoo! Finance]
12/2
07:00 am
rdhl
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
Medium
Report
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
10/28
07:00 am
rdhl
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
Low
Report
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
10/22
07:00 am
rdhl
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
Medium
Report
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
10/14
07:00 am
rdhl
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
Medium
Report
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
10/1
07:00 am
rdhl
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
Medium
Report
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
9/30
07:00 am
rdhl
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
Low
Report
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041